Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 4/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.31 |
| ▸ | GSR | P00390 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9880269 | 0.83 | NPSR1 (0.45) | NPSR1HSD17B10MAPT | |
| SCHEMBL20929588 | 0.69 | MEN1 (0.47) | PDE2AHSD17B10PDE4DPDE11APDE10A | |
| SCHEMBL18805394 | 0.68 | PDE2A (0.45) | PDE2AAOC3PDE4DPDE11APDE10A | |
| SCHEMBL11946718 | 0.67 | AAK1 (0.42) | PDE2AAOC3MAPTS1PR1ATM | |
| SCHEMBL18691767 | 0.65 | ALDH1A1 (0.53) | BRD4PDE2AHSD17B10AOC3PDE4D | |
| SCHEMBL9880260 | 0.63 | KDM5B (0.31) | KDM5B | |
| SCHEMBL25617163 | 0.62 | TOP2A (0.37) | HSD17B10MAPTATM | |
| SCHEMBL22016213 | 0.62 | MAPT (0.40) | MAPT | |
| SCHEMBL17570864 | 0.62 | MEN1 (0.50) | PDE2AHSD17B10PDE10AGSRMAPT | |
| SCHEMBL17570839 | 0.62 | MEN1 (0.50) | PDE2AHSD17B10PDE10AGSRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46375-E1 | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative | SHIONOGI & CO., LTD. (JP) | 2017-04-25 | — | — | US | disclosed |
| US-RE46365-E1 | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative | SHIONOGI & CO., LTD. (JP) | 2017-04-11 | — | — | US | disclosed |
| US-8536192-B2 | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative | SHIONOGI & CO. LTD. (JP) | 2013-09-17 | — | — | US | disclosed |
| US-20120135978-A1 | 6,7-UNSATURATED-7-CARBAMOYL SUBSTITUTED MORPHINAN DERIVATIVE | SHIONOGI & CO., LTD. | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135978-A1 | 6,7-UNSATURATED-7-CARBAMOYL SUBSTITUTED MORPHINAN DERIVATIVE | HRH2, GPR27, HRH4 | BRD4 2487/4885PDE2A 1039/4885NPSR1 918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.